Research Status of CAR-T Cell Immunotherapy in Tumor Treatment

In recent years, chimeric antigen receptor T-cell (CAR-T) therapy has made breakthroughs in the treatment of hematological tumors. However, due to different characteristics solid tumors from tumors, CAR-T not achieved good efficacy The key factors limiting mainly include tumor cells themselves and their special microenvironment (TME), which damage function multiple processes such as infiltration tissue sites, maintaining anti-tumor activity TME, target recognition killing by CAR-T. To solve these problems, more preclinical studies have proposed potentially effective solutions, corresponding clinical been carried out one after another. this article, existing challenges optimization strategies cell for will be reviewed, provide a reference future exploration therapy.